What are the latest funding news in the femtech market? (June 2026)
Download our beautiful pitch about the femtech market
In our femtech market deck, you will find everything you need to understand the market
Femtech funding in June 2026 showed a market that is still small in deal count but increasingly broad in clinical scope.
The latest rounds covered fertility financing, maternal monitoring, menstrual care, breast cancer AI, menopause-related bone health, pelvic health, and ovarian cancer diagnostics.
The largest disclosed round was Gaia’s $100M debt facility, while most equity rounds stayed in the seed to Series A range.
And if you want to better understand this new industry, you can download our pitch covering the femtech market.
Insights
- Fertility remained the strongest funding theme, with Gaia, Future Fertility, ONTO Health, and Flora Fertility together representing more than $129M in disclosed femtech market capital.
- Debt financing changed the picture: Gaia alone accounted for about 57% of the disclosed capital across these 12 latest femtech funding rounds.
- Clinical femtech is moving beyond apps, with several deals backing regulated or medical-grade products in maternal monitoring, breast cancer AI, bone health, and ovarian cancer diagnostics.
- The U.S. remained the main commercial target, but the deal list also showed active femtech funding in India, Japan, Australia, Canada, the Netherlands, and the UK.
- Seed and Series A rounds dominated the list, which suggests investors are still mostly backing early commercialization rather than late-stage femtech scale-ups.
- Menopause-related care appeared through Osteoboost Health, but the category still represented only one deal in this latest set despite strong demographic demand.
- Women’s oncology is becoming more visible inside the femtech market, with ScreenPoint Medical and Proseek Bio both raising for cancer detection and diagnostic triage.
- Hardware-enabled femtech attracted meaningful investor interest, especially in continence care, labor monitoring, and postmenopausal bone health.
- The latest rounds show a split market: some companies sell consumer access products, while others sell into clinics, hospitals, payers, and care providers.
As this chart shows, and as featured in our femtech market deck, search interest in femtech has increased significantly
Summary table of the latest funding deals in the femtech market as of June 2026
We define the femtech market as technology-enabled products and services that address women’s reproductive and other female-specific health needs.
We include solutions focused on menstrual and cycle health, fertility and contraception, pregnancy and postpartum, menopause, pelvic and sexual health, and clinically oriented tools for conditions that predominantly or uniquely affect women, such as breast and gynecological cancers.
We exclude general-purpose health, wellness, fitness, mental health, and consumer apps that are not specifically designed around women’s biology, care pathways, or life stages.
You can also read our detailed analysis to understand how funding activity in the femtech market has evolved over the last few years.
We also have a quarter-by-quarter analysis of funding activity in the market here.
Finally, you can check our complete list of fundraising deals for the femtech market (we update this list every quarter) as well as our ranking of the most funded startups.
| Name | When | Amount in $ | Round Type | Category |
|---|---|---|---|---|
| Joyvié Health | 5 June 2026 | $1.04M | Pre-seed | Pelvic health & incontinence care |
| Gaia | 27 May 2026 | $100M | Debt facility | Fertility financing & reproductive-health access |
| Oli | 26 May 2026 | $6.5M | Series A3 | Pregnancy & maternal-fetal monitoring |
| HealthFab | 4 May 2026 | ~$2.4M | Series A | Menstrual health & period care |
| Flora | 4 May 2026 | ~$1.5M | Growth funding | Women’s health data & life-stage platform |
| Future Fertility | 27 April 2026 | $4.1M | Series A | Fertility & IVF AI |
| ScreenPoint Medical | 17 April 2026 | $14M | Growth financing | Breast cancer AI |
| ONTO Health | 17 April 2026 | $20M | Series A | Fertility care platform |
| Osteoboost Health | 9 April 2026 | $8M | Financing round | Menopause & bone health |
| Flora Fertility | 7 April 2026 | $5M | Seed | Fertility insurance & reproductive-health access |
| Proseek Bio | 8 April 2026 | ~$1.0M | Seed | Ovarian cancer diagnostics |
| SimpliFed | 7 April 2026 | $10.8M | Series A | Pregnancy, postpartum & lactation care |
All the latest funding deals during in the femtech market as of June 2026
Joyvié Health raised $1.04M in June 2026.
When was it?
Joyvié Health announced the deal on 5 June 2026.
Who are they?
Joyvié Health makes continence underwear designed to separate stool from skin, reduce skin breakdown, and support dignified care.
Geographical focus?
Joyvié Health is focused on the UK, especially care homes, hospitals, domiciliary care, and early direct-to-consumer customers.
Why do we include them in the femtech market?
Joyvié Health is included as a pelvic-health and incontinence-care company because the product targets a condition that disproportionately affects women as patients and caregivers.
What is the company stage?
Joyvié Health is pre-commercial, with pilots and a direct-to-consumer launch planned.
How much did they raise?
Joyvié Health raised $1.04M, equivalent to about €897k.
What round is it?
Joyvié Health raised a pre-seed round made up of grant funding and investment.
Why did they raise?
Joyvié Health raised to fund clinical pilots, first hires, partnerships, and the company’s direct-to-consumer launch.
Gaia secured a $100M debt facility in May 2026.
When was it?
Gaia announced the debt facility on 27 May 2026.
Who are they?
Gaia offers fertility-clinic matching and outcome-protected financing for IVF and egg freezing.
Geographical focus?
Gaia is focused on the United States, where the company works across clinic locations in many states.
Why do we include them in the femtech market?
Gaia is included as a fertility-financing company because the platform is built around IVF, embryo transfer, and egg-freezing access.
What is the company stage?
Gaia is in growth stage, with memberships and clinic coverage already in market.
How much did they raise?
Gaia secured $100M for this financing facility.
What round is it?
Gaia secured a debt facility, not a traditional equity round.
Why did they raise?
Gaia raised to scale outcome-protected fertility financing across the U.S.
This chart, included in our femtech market deck, compares the main business model options for menopause telehealth platforms
Oli raised $6.5M in May 2026.
When was it?
Oli announced the round on 26 May 2026.
Who are they?
Oli is a wireless wearable from Baymatob that monitors maternal and fetal signals during labor.
Geographical focus?
Oli is focused on Australia and the United States, with clinical trials and regulatory work in both markets.
Why do we include them in the femtech market?
Oli is included as pregnancy and maternal-fetal monitoring technology because the product is built for labor risk prediction and birth-complication detection.
What is the company stage?
Oli is in a late product and regulatory pre-market stage, with pivotal trials underway.
How much did they raise?
Oli raised $6.5M in this round.
What round is it?
Oli raised a Series A3 round.
Why did they raise?
Oli raised to complete pivotal trials, advance TGA and FDA submissions, establish manufacturing, and prepare for launch.
HealthFab raised about $2.4M in May 2026.
When was it?
HealthFab announced the round on 4 May 2026.
Who are they?
HealthFab sells reusable period underwear and is building a broader menstrual-care platform.
Geographical focus?
HealthFab is focused on India, with both direct-to-consumer and offline distribution.
Why do we include them in the femtech market?
HealthFab is included as a menstrual-health company because the core product and expansion plan are directly tied to period care.
What is the company stage?
HealthFab is in early growth, with a reported user base and revenue traction.
How much did they raise?
HealthFab raised about $2.4M, reported as ₹20 crore.
What round is it?
HealthFab raised a Series A round, according to the reporting available.
Why did they raise?
HealthFab raised to expand beyond period underwear, strengthen offline distribution, and invest in research and development.
This chart, included in our femtech market deck, shows how Flo Health is capturing share in femtech
Flora raised about $1.5M in May 2026.
When was it?
Flora was covered on 4 May 2026, after the company announced the raise in late April.
Who are they?
Flora is a Kyoto-based AI femtech company with products for women’s health data, workplace wellbeing, and consumer tracking.
Geographical focus?
Flora is focused on Asia, with activity across Japan, South Korea, Taiwan, India, and Vietnam.
Why do we include them in the femtech market?
Flora is included as a women’s health data and life-stage platform because the products cover menstruation, fertility, pregnancy, postpartum, and menopause.
What is the company stage?
Flora is in early growth, with consumer and B2B products already in market.
How much did they raise?
Flora raised about $1.5M, reported as ¥230M.
What round is it?
Flora raised a growth funding round rather than a classic named Series A or Series B.
Why did they raise?
Flora raised to scale Wellflow, Flora Expert, and Moonly, while hiring more engineers and data scientists.
Future Fertility raised $4.1M in April 2026.
When was it?
Future Fertility announced the round on 27 April 2026.
Who are they?
Future Fertility builds AI tools that assess egg quality for IVF, egg freezing, and donor programs.
Geographical focus?
Future Fertility is based in Toronto and sells globally, with deployment across clinics in many countries.
Why do we include them in the femtech market?
Future Fertility is included as fertility and IVF lab AI because the company focuses on oocyte quality assessment and fertility-treatment decision support.
What is the company stage?
Future Fertility is in growth and commercialization stage, with clinic deployment already underway.
How much did they raise?
Future Fertility raised $4.1M in this round.
What round is it?
Future Fertility raised a Series A round.
Why did they raise?
Future Fertility raised to expand in Asia-Pacific, support U.S. market entry, and broaden the company’s IVF AI platform.
In our femtech market deck, we identify pain points entrepreneurs should prioritize
ScreenPoint Medical raised $14M in April 2026.
When was it?
ScreenPoint Medical announced the funding on 17 April 2026, with additional coverage on 20 April.
Who are they?
ScreenPoint Medical makes AI software for breast-cancer detection and risk assessment in mammography.
Geographical focus?
ScreenPoint Medical is Netherlands-based and has global deployment across more than 30 countries.
Why do we include them in the femtech market?
ScreenPoint Medical is included as women’s oncology AI because breast-cancer screening is a female-specific clinical care pathway in this market definition.
What is the company stage?
ScreenPoint Medical is in commercial growth, with millions of mammograms already processed.
How much did they raise?
ScreenPoint Medical raised $14M in new funding, alongside $2M in non-dilutive grants.
What round is it?
ScreenPoint Medical raised an undisclosed growth financing round from existing backers.
Why did they raise?
ScreenPoint Medical raised to scale global commercialization, continue product innovation, and expand across the breast-cancer care continuum.
ONTO Health raised $20M in April 2026.
When was it?
ONTO Health announced the round on 17 April 2026.
Who are they?
ONTO Health is an AI-enabled, physician-led care provider focused on fertility and longevity.
Geographical focus?
ONTO Health is focused on the United States, with planned expansion into the Gulf Cooperation Council region.
Why do we include them in the femtech market?
ONTO Health is included as a fertility-care platform because fertility care is the entry point and core clinical workflow.
What is the company stage?
ONTO Health is in early growth and expansion stage, with clinical operations already active.
How much did they raise?
ONTO Health raised $20M in this round.
What round is it?
ONTO Health raised a Series A round.
Why did they raise?
ONTO Health raised to expand fertility-care operations in the U.S. and enter the GCC region through Humania’s healthcare network.
This market map, featured in our femtech market deck, highlights top companies and startups in the femtech market
Osteoboost Health raised $8M in April 2026.
When was it?
Osteoboost Health announced the financing on 9 April 2026.
Who are they?
Osteoboost Health makes an FDA-cleared prescription wearable for low bone density in postmenopausal women with osteopenia.
Geographical focus?
Osteoboost Health is focused on the United States.
Why do we include them in the femtech market?
Osteoboost Health is included as menopause and female-specific bone health because the device is clinically positioned for postmenopausal women.
What is the company stage?
Osteoboost Health is in commercial growth, with devices shipping and physician prescribing activity reported.
How much did they raise?
Osteoboost Health raised $8M in this financing round.
What round is it?
Osteoboost Health raised an undisclosed financing round.
Why did they raise?
Osteoboost Health raised to scale manufacturing, expand clinical research, and broaden commercial reach.
Flora Fertility raised $5M in April 2026.
When was it?
Flora Fertility was reported on 7 April 2026, with another listing dated 10 April 2026.
Who are they?
Flora Fertility builds individually owned fertility insurance that is portable and not tied to employer benefits.
Geographical focus?
Flora Fertility is initially focused on the United States, with Canada expected to follow.
Why do we include them in the femtech market?
Flora Fertility is included as fertility insurance because the product covers diagnostics, medication, IUI, and IVF.
What is the company stage?
Flora Fertility is in seed stage and early commercial launch.
How much did they raise?
Flora Fertility raised $5M in this round.
What round is it?
Flora Fertility raised a Seed round.
Why did they raise?
Flora Fertility raised to expand access to fertility coverage and scale the company’s AI-driven underwriting and insurance model.
This chart, included in our femtech market deck, shows annual funding in femtech startups
Proseek Bio raised about $1.0M in April 2026.
When was it?
Proseek Bio was reported on 8 April 2026.
Who are they?
Proseek Bio is developing OC-Triage, a blood test to improve ovarian-cancer diagnostic triage.
Geographical focus?
Proseek Bio is focused on Australia, starting from Brisbane with validation and commercialization work.
Why do we include them in the femtech market?
Proseek Bio is included as gynecologic cancer diagnostics because ovarian cancer is a female-specific clinical condition.
What is the company stage?
Proseek Bio is seed stage and is working toward clinical lab deployment, validation, and later commercialization.
How much did they raise?
Proseek Bio raised about $1.0M, reported as A$1.5M.
What round is it?
Proseek Bio raised an oversubscribed Seed round.
Why did they raise?
Proseek Bio raised to advance OC-Triage and reduce unnecessary invasive surgeries for suspected ovarian cancer.
SimpliFed raised $10.8M in April 2026.
When was it?
SimpliFed announced the round on 7 April 2026.
Who are they?
SimpliFed provides virtual breastfeeding, baby-feeding, and maternal-health support from pregnancy through postpartum.
Geographical focus?
SimpliFed is focused on the U.S. healthcare market, especially health plans, health systems, and OB/GYN partners.
Why do we include them in the femtech market?
SimpliFed is included as pregnancy, postpartum, and lactation care because the core service supports maternal and infant feeding care.
What is the company stage?
SimpliFed is in Series A and early growth stage, expanding from lactation into broader virtual perinatal care.
How much did they raise?
SimpliFed raised $10.8M in this round.
What round is it?
SimpliFed raised an oversubscribed Series A round.
Why did they raise?
SimpliFed raised to scale lactation services, add virtual OB services, and expand the company’s maternal-health platform.
Related blog posts
- How strong is fundraising in the femtech market right now?
- The most recent news in the femtech market
- What is the true size of the femtech market?
- How funding activity has evolved in the femtech market
- What are the key fundraising trends in the femtech market?
- All the funding deals announced in the femtech market
- Which companies have raised the most funding in the femtech market?
- Which companies are the most valued in the femtech market?
